Ozempic is best known for shrinking waistlines. It may also be shrinking the likelihood that someone acts on a violent impulse.
A Rutgers University study published June 17, 2026 in the journal Criminology — the flagship peer-reviewed journal of the American Society of Criminology — has found that GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are associated with a substantially weaker link between impulsivity, alcohol use, and violent behavior. The study was highlighted June 23, 2026 on Medscape in a report on what GLP-1s are teaching science about compulsive behavior — underscoring that this finding is now being taken seriously in clinical medicine, not just criminology.